Nonsteroidal Anti-inflammatory Drugs for Sciatica: An Updated Cochrane Review.

Rasmussen-Barr, Eva; Held, Ulrike; Grooten, Wilhelmus J A; Roelofs, Pepijn D D M; Koes, Bart W; van Tulder, Maurits W; Wertli, Maria Monika (2017). Nonsteroidal Anti-inflammatory Drugs for Sciatica: An Updated Cochrane Review. Spine, 42(8), pp. 586-594. Wolters Kluwer Health 10.1097/BRS.0000000000002092

[img]
Preview
Text
00007632-201704150-00014.pdf - Published Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

STUDY DESIGN

Systematic review and meta-analysis.

OBJECTIVE

To determine the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) on pain reduction, overall improvement, and reported adverse effects in people with sciatica.

SUMMARY OF BACKGROUND DATA

NSAIDs are one of the most frequently prescribed drugs for sciatica.

METHODS

We updated a 2008 Cochrane Review through June 2015. Randomized controlled trials that compared NSAIDs with placebo, with other NSAIDs, or with other medication were included. Outcomes included pain using mean difference (MD, 95% confidence intervals [95% CI]). For global improvement and adverse effects risk ratios (RR, 95% CI) were used. We assessed level of evidence using the Grades of Recommendation, Assessment, Development and Evaluation approach.

RESULTS

Ten trials were included (N = 1651). Nine out of 10 trials were assessed at high risk of bias. For pain reduction (visual analog scale, 0 to 100) NSAIDs were no more effective than placebo (MD -4.56, 95% CI -11.11 to 1.99, quality of evidence: very low). For global improvement NSAIDs were more effective than placebo (RR 1.14 [95% CI 1.03 to 1.27], low quality of evidence). One trial reported the effect of NSAIDs on disability with very low-quality evidence that NSAIDs are no more effective than placebo. There was low-quality evidence that the risk for adverse effects is higher for NSAID than placebo (RR 1.40, 95% CI 1.02 to 1.93).

CONCLUSION

Our findings show very low-quality evidence that the efficacy of NSAIDs for pain reduction is comparable with that of placebo, low-quality evidence that NSAIDs is better than placebo for global improvement and low-quality evidence for higher risk of adverse effects using NSAIDs compared with placebo. The findings must be interpreted with caution, due to small study samples, inconsistent results, and a high risk of bias in the included trials.

LEVEL OF EVIDENCE

1.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine

UniBE Contributor:

Wertli, Maria Monika

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1528-1159

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Jacques Donzé

Date Deposited:

18 Jun 2018 13:56

Last Modified:

05 Dec 2022 15:10

Publisher DOI:

10.1097/BRS.0000000000002092

PubMed ID:

28399072

BORIS DOI:

10.7892/boris.110678

URI:

https://boris.unibe.ch/id/eprint/110678

Actions (login required)

Edit item Edit item
Provide Feedback